机译:PTEN缺乏促进胆囊癌中蛋白酶体抑制剂硼替佐米的治疗性脆弱性
Second Mil Med Univ Eastern Hepatobiliary Surg Inst Int Cooperat Lab Signal Transduct Shanghai;
Natl Ctr Liver Canc Shanghai 201805 Peoples R China;
Second Mil Med Univ Eastern Hepatobiliary Surg Hosp Dept Surg Shanghai 200438 Peoples R China;
Second Mil Med Univ Eastern Hepatobiliary Surg Inst Int Cooperat Lab Signal Transduct Shanghai;
Second Mil Med Univ Eastern Hepatobiliary Surg Inst Int Cooperat Lab Signal Transduct Shanghai;
Natl Ctr Liver Canc Shanghai 201805 Peoples R China;
Soochow Univ Childrens Hosp Suzhou 215025 Peoples R China;
Second Mil Med Univ Eastern Hepatobiliary Surg Hosp Dept Surg Shanghai 200438 Peoples R China;
Second Mil Med Univ Eastern Hepatobiliary Surg Hosp Dept Surg Shanghai 200438 Peoples R China;
Natl Ctr Liver Canc Shanghai 201805 Peoples R China;
Second Mil Med Univ Eastern Hepatobiliary Surg Inst Int Cooperat Lab Signal Transduct Shanghai;
Second Mil Med Univ Eastern Hepatobiliary Surg Inst Int Cooperat Lab Signal Transduct Shanghai;
Gallbladder cancer; PTEN; Bortezomib; Proteasome; BACH1;
机译:基于蛋白酶体抑制剂的抗癌治疗概述:硼替佐米和第二代蛋白酶体抑制剂与泛素-蛋白酶体系统的下一代抑制剂的前景
机译:Bortezomib - 癌症治疗的第一治疗蛋白酶体抑制剂:专利文献综述
机译:蛋白酶体抑制剂硼替佐米可增加PTEN表达并增强曲妥珠单抗耐药细胞中曲妥珠单抗诱导的生长抑制。
机译:Bortezomib(PS-341,Velcade〜(R)的非临床发现和发展)一种治疗癌症的蛋白酶体抑制剂
机译:硼替佐米诱导内质网状应力:一种胰腺癌的新治疗策略。
机译:基于蛋白酶体抑制剂的抗癌治疗概述:硼替佐米和第二代蛋白酶体抑制剂与泛素-蛋白酶体系统的下一代抑制剂的观点
机译:蛋白酶体抑制剂的抗癌疗法概述:硼卓和第二代蛋白酶体抑制剂对泛素 - 蛋白酶体系的未来产生抑制剂的透视
机译:检测乳腺癌中使用shRNa文库修饰蛋白酶体抑制剂敏感性的基因。